3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Basal Cell
6
Skin Neoplasms
2
Keratosis, Actinic
2
Squamous Cell Carcinoma of Head and Neck
1
Non-melanoma Skin Cancer
1
Nevus, Pigmented
1
Mouth Neoplasms
1
Mouth Diseases
1
Mixed Tumor, Malignant
1
Melanoma
1
Lichen Planus, Oral
1
Leukoplakia, Oral
1
Keratosis, Seborrheic
1
Keratosis
1
Graft vs Host Disease
1
Disease
1
Carcinoma
1
Bowen's Disease
1
Actinic cheilitis
1
Interventions
pembrolizumab
8
Nivolumab
4
fludarabine
2
Cyclophosphamide
2
sonidegib
1
obinutuzumab
1
methyl 5-aminolevulinate
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
durvalumab
1
daromun
1
cabozantinib
1
avelumab
1
atezolizumab
1
advexin
1
Tomography, Optical Coherence
1
Therapeutics
1
Taxes
1
Specimen Handling
1
Radiotherapy
1
ProMune
1
Pemetrexed
1
Paclitaxel
1
Oncolytic Virotherapy
1
Mesna
1
Magnetic Resonance Spectroscopy
1
MAPRE1 protein, human
1
Lutetium-177
1
Interleukin-2
1
HhAntag691
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Tomography, Optical Coherence
×
Dermatologic
×
Clear all
NCT02851693
2019-04-04
OCTSKIN
Centre Hospitalier Universitaire de Saint Etienne
Phase NA
Withdrawn